ŌURA Announces Be the Expert in You Campaign to Promote Body Literacy for Women

ŌURA Announces Be the Expert in You Campaign to Promote Body Literacy for Women




ŌURA Announces Be the Expert in You Campaign to Promote Body Literacy for Women

Feature enhancements, new research studies, and a growing partnership ecosystem all part of an ongoing commitment to support women throughout all phases of life

SAN FRANCISCO–(BUSINESS WIRE)–In honor of Women’s Health Month, ŌURA, maker of Oura Ring, the most accurate and trusted smart ring, today launched Be the Expert in You, a month-long, multi-channel campaign dedicated to giving every woman’s body a voice. The Finnish company has been steadily adding to its slate of women’s health features and research since 2021 and, throughout the month of May, will be introducing additional features, innovative studies, and personal stories from both employees and members to promote body literacy for women of all ages.




Be the Expert in You marks the latest development in Oura’s commitment to delivering products and research that are designed for women and provide a holistic approach to health. This is the most recent of many women’s health investments from the company, including the launch of its Pregnancy Insights feature, the publication of trailblazing fertility research with the University of California, Berkeley, and the first wearable integration with FDA-cleared birth control app Natural Cycles.

“Female health conditions receive only one percent of global healthcare research funding, which has created a significant knowledge gap that hinders women from fully understanding basic information about their bodies,” said Dr. Neta Gotlieb, product manager for women’s health at Oura. “For example, a recent survey found that one in four women do not understand their menstrual cycle. Oura is uniquely positioned to be a critical partner for women to close this information gap and become experts in themselves through comprehensive data, personalized insights, and ongoing research on a variety of women’s health topics.”

Introducing More Features Designed for Women

In the coming weeks, Oura will introduce two new women’s health updates in the Oura App. The latest enhancement to Oura’s period tracking feature, Cycle Insights, will provide members with even more details about their cycles. Now, users will receive data about their cycle regularity, typical cycle length, and typical period length so they can learn patterns and seek care if needed, especially those with irregular cycles and women in perimenopause. Oura members will also be able to share this information through the new Cycle Insights Report, a comprehensive report designed in partnership with members of Oura’s Medical Advisory Board. Cycle Insights Report will include cycle length, period length, temperature variation charts, cycle variability, and more to help women feel seen and empowered in conversations with their healthcare professionals.

“Personal data can be an extremely validating tool for women who have irregular cycles, but until recently, it has not been widely accessible,” said Holly Shelton, chief product officer at Oura. “Fifty-nine percent of women have sought treatment from doctors who did not believe them or ignored their needs, and our hope is that we can equip our members with the tools needed to advocate for themselves and their health.”

In addition to Cycle Insights, Oura will update the algorithm behind its Readiness Score to take into account the natural physiological fluctuations that occur throughout a woman’s menstrual cycle, such as increased temperature and heart rate and decreased heart rate variability (HRV) during the luteal phase. With this update, members enrolled in Cycle Insights will not see decreases in their Readiness Scores as a result of their normal, cyclical biometric changes, making it a more accurate measurement of wellness.

“Female physiology differs dramatically from male physiology, which makes it necessary to create algorithms that address the needs of both,” said Shelton. “We are committed to continuing to improve the Oura experience for our female members by delivering data and insights that accurately and comprehensively explain what’s happening in their bodies every day.”

Expanding Research for Underserved Populations

On May 16, at the Women of Wearables Menopause 2.0 Conference, Oura and Clue will unveil new research findings from both Oura Ring and the Clue App that illustrate the impacts of perimenopause and menopause. As part of that research, a recent analysis of Oura member tagging data found that when comparing women ages 45-54 to women ages 25-34, women in the perimenopausal age range are 56% more likely to tag migraine, 57% more likely to tag hot flashes, and 41% more likely to tag night sweats. These preliminary findings mark the first step in an exciting collaboration between the two organizations to shed light on the myriad of ways that menopause can affect overall well-being, with an additional collaboration with researchers at the University of California, Berkeley, coming soon.

“Our science agenda to advance women’s health consists of several large-scale studies with leading academic institutions, and we are proud to introduce new research during the month of May that will give more women a better understanding of their bodies,” said Alicia Clausel, clinical research scientist at Oura. “No matter your age or your fertility status, every woman should have the resources they need to manage their health.”

Growing an Ecosystem of Women’s Health Partners

To continue delivering a comprehensive product offering and expansive research agenda, Oura is committed to establishing connections with leading women’s health partners. In 2022, Oura partnered with Natural Cycles, the first FDA-cleared birth control app, to allow members to sync temperature-trend data straight from the Oura Ring, offering a convenient and accurate alternative to measuring their temperature manually. As of March 2024, 30% of female Oura members in their thirties and 41% of female members in their twenties were using the Oura and Natural Cycles integration.

Over the last year, Oura has expanded its women’s health integrations with other leaders in the space, including Clue, Glow, and Flo, to allow members to dive deeper into their data and insights using whichever platform best meets their needs. The company is actively growing this list to include additional women’s health partners so that no matter where or how a person chooses to track, Oura can be a measurement companion.

Designing the Future of Wearable Tech for Women, by Women

Oura is proud to have a strong group of women at the helm of these features, research studies, and partnerships. Throughout the month of May, many of them will share their own Oura stories that have helped shape the company’s vision and mission to give every body a voice. Among them is Dorothy Kilroy, Oura’s chief commercial officer, who has spearheaded Oura’s partnership efforts in the women’s health space and grown the commercial business to include collaborations with over 800 organizations.

“When we think of women’s health, we tend to boil it down to reproductive health, when in reality, it is so much more than that,” said Dorothy Kilroy, chief commercial officer at Oura. “For me personally, juggling being a mom and my professional career was extremely overwhelming. Seeing my scores and Oura data has helped inform me what’s happening to my body beyond my cycle. I can see the bigger shifts in my ability to manage stress, and how my transition to menopause was impacting my sleep, my activity, and even my mood. We are finally building tools to connect the dots for women throughout all phases of their lives.”

The Be the Expert in You campaign is a multi-channel media campaign featuring two full-page print advertisements in The New York Times Style Section, a custom-branded video in collaboration with Vogue, and several digital display advertisements. In addition, the company will be releasing four videos throughout the month to tell the stories of the women working behind the scenes at Oura and the motivation behind making Oura Ring the smart ring of choice for women.

For more information, visit ouraring.com/womens-health.

About ŌURA:

ŌURA is the company behind Oura Ring—the smart ring that delivers personalized health data, insights, and daily guidance. With sleep as its foundation, Oura Membership fosters healthy habits to make wellness and recovery a mindful, daily practice. Validated against medical gold standards and driven by continuous monitoring of individual biometrics, the lightweight and comfortable Oura Ring is one of the most accurate wearables available. For organizations, Oura For Business connects individual well-being with collective outcomes by making performance measurable, actionable, and attainable. Founded in Finland with offices in Oulu, Helsinki, San Francisco, and San Diego, ŌURA has raised more than $350 million and is valued at $2.55 billion. For more information, please visit http://ouraring.com/.

Oura Ring is not a medical device and is not intended to diagnose, treat, cure, monitor, or prevent medical conditions/illnesses.

Contacts

Kristin Messina, ŌURA

kristin.messina@ouraring.com
press@ouraring.com

Padraig McDonnell Assumes Agilent CEO Role

Padraig McDonnell Assumes Agilent CEO Role




Padraig McDonnell Assumes Agilent CEO Role

SANTA CLARA, Calif.–(BUSINESS WIRE)–Agilent Technologies Inc. (NYSE:A) today announced that Padraig McDonnell has assumed the role of Agilent CEO, effective immediately. His appointment is part of the company’s CEO transition plan announced Feb. 21. McDonnell is the fourth CEO in Agilent’s history and succeeds Mike McMullen, who will serve as an adviser until he retires Oct. 31.




It’s an incredible honor to serve as CEO of this great company that impacts the world by advancing the quality of life,” McDonnell said. “I’m proud of how we forge partnerships with our customers to help them bring great science to life, and I’m excited to lead Agilent because of the possibilities that lie ahead for us.”

Based on his proven record of success, we firmly believe Padraig McDonnell is the right choice to lead Agilent,” said Koh Boon Hwee, chairman of Agilent’s Board of Directors. “We look forward to working with him to build on that success as CEO.”

Before being named CEO-elect in February, McDonnell, 52, had served as president of the Agilent CrossLab Group (ACG) since May 2020. His role leading ACG expanded in November 2021, when he was also named to lead the company’s commercial organization as chief commercial officer.

As President of ACG, McDonnell drove outstanding growth in Agilent’s services business, with significant improvements in profitability and customer satisfaction. As chief commercial officer, he also led the transformation of the customer experience at Agilent by improving the end-to-end customer journey and customer lifetime value.

Prior to becoming ACG president, McDonnell was vice president and general manager of Agilent’s Chemistries and Supplies Division, a role to which he was named in 2017. He has been in the analytical- and scientific-instrument industry for 26 years, starting his career with Agilent’s predecessor Hewlett-Packard Co. in 1998.

With Padraig at the helm, the future is bright for Agilent,” McMullen said. “His leadership skills, knowledge and customer focus will serve the company well for many years to come.”

For more information regarding Agilent’s new CEO, please visit the Agilent website.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers’ most challenging questions. The company generated revenue of $6.83 billion in fiscal 2023 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Contacts

Media Contact:
Tom Beermann

+1 408-386-5892

tom.beermann@agilent.com

Investor Contact:
Parmeet Ahuja

+1 408-345-8948

parmeet_ahuja@agilent.com

 

Endeavor BioMedicines to Present New Data From Phase 2a Clinical Trial of ENV-101 at American Thoracic Society 2024 International Conference

Endeavor BioMedicines to Present New Data From Phase 2a Clinical Trial of ENV-101 at American Thoracic Society 2024 International Conference




Endeavor BioMedicines to Present New Data From Phase 2a Clinical Trial of ENV-101 at American Thoracic Society 2024 International Conference

Data from Phase 2a trial of novel Hedgehog (Hh) signaling pathway inhibitor in patients with idiopathic pulmonary fibrosis selected for featured late-breaking oral presentation on May 19

SAN DIEGO–(BUSINESS WIRE)–Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced that data from a completed Phase 2a clinical trial evaluating the company’s lead investigational candidate ENV-101 in patients with idiopathic pulmonary fibrosis (IPF) will be presented for the first time in a late-breaking oral session at the American Thoracic Society 2024 (ATS 2024) International Conference. ATS 2024 will take place May 17-22, 2024, in San Diego.


The Phase 2a, randomized, double-blind, placebo-controlled clinical trial (NCT04968574) evaluated the safety and efficacy of ENV-101 vs. placebo in 41 patients with confirmed IPF who were treated for 12 weeks.

Following are details about the ENV-101 oral presentation at ATS 2024:

  • Title: ENV-101, A Novel Hedgehog Inhibitor, Increases Lung Function, and Reduces Lung Fibrosis in Patients With Idiopathic Pulmonary Fibrosis: Results From a Randomized, Double-blind, Placebo-controlled Phase 2 Trial
  • Presenter: Toby M. Maher, M.D., Ph.D., Professor of Medicine and Director of Interstitial Lung Disease at Keck School of Medicine, University of Southern California, Los Angeles
  • Session: A-18 – Fixing What’s Broken: Novel Therapeutics for Lung Remodeling
  • Date and Time: May 19, 2024, 10:51-11:03 a.m. PT
  • Location: San Diego Convention Center, Room 8 (Upper Level)

We look forward to sharing the results from the Phase 2a trial of ENV-101 with the pulmonology community for the first time at ATS 2024,” said Paul A. Frohna, M.D., Ph.D., Pharm.D., Chief Medical Officer, Endeavor BioMedicines. “There is a tremendous need for new therapies that have the potential to reverse lung fibrosis and improve lung function in patients with IPF, and these data suggest ENV-101 could be an important new option for patients.”

ENV-101 blocks a cellular wound-healing pathway known as Hedgehog (Hh) that is abnormally activated in fibrotic lung diseases such as IPF and causes the buildup of scar tissue in the lungs. Current standard-of-care therapies do not address the underlying cause of IPF. They slow the decline of lung function, but do not stop or reverse it, and they have tolerability issues that limit their long-term use in most patients. Based on results from the Phase 2a trial of ENV-101, Endeavor BioMedicines intends to initiate a Phase 2 trial in patients with IPF and in a parallel cohort, patients with progressive pulmonary fibrosis (PPF), in 2024.

About Idiopathic Pulmonary Fibrosis

IPF is a chronic, progressive lung disease that affects more than 100,000 adults in the United States. Although the exact cause of IPF is unknown, various environmental factors can deliver repeated injuries to lung cells that trigger abnormal wound-healing processes and life-threatening lung scarring. IPF is a chronic disease with limited treatment options and a very poor prognosis: the average life expectancy is only three to five years after diagnosis.

About ENV-101

Endeavor BioMedicines’ investigational medicine ENV-101 is a Hedgehog signaling pathway inhibitor. By binding to and inhibiting a key receptor in the Hedgehog pathway, ENV-101 stops the abnormal accumulation of the myofibroblasts that cause fibrosis. This may resolve the excessive wound-healing process seen in IPF and PPF, creating the potential to reverse fibrosis and improve lung volume and function.

About Endeavor BioMedicines

Endeavor BioMedicines is a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases. Endeavor’s lead candidate, ENV-101, is an inhibitor of the Hedgehog signaling pathway in clinical development for the treatment of IPF and PPF. The company’s second candidate, ENV-501, is a HER3 antibody-drug conjugate (ADC) for the treatment of HER3-positive solid tumors. More information is available at www.endeavorbiomedicines.com and on LinkedIn or X.

Contacts

Media Contact:
Andrea Cohen

917-209-7163

AndreaCohen@sambrown.com

ReCode Therapeutics to Participate in May Conferences

ReCode Therapeutics to Participate in May Conferences




ReCode Therapeutics to Participate in May Conferences

MENLO PARK, Calif.–(BUSINESS WIRE)–ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced that company management will participate in the upcoming May conferences:


Wells Fargo Virtual Private Biotech Symposium

Format: 1×1 Investor Meetings

Date: May 6, 2024

Location: Virtual

Capital One Biotech – Life Sciences Disruptors Event

Format: Panel Discussion on “The Next Wave of mRNA and Gene Correction Therapeutics”

Date: May 14, 2024

Time: 1:45 p.m. ET

Location: New York

Virtual Piper Sandler Lung Day Post-ATS

Format: Fireside Chat

Date: May 23, 2024

Time: 12:00 – 12:25 p.m. ET

Location: Virtual

About ReCode Therapeutics

ReCode Therapeutics is a clinical-stage genetic medicines company using precision delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform enables highly precise and targeted delivery of genetic medicines directly to the organs, tissues and cells implicated in disease, enabling improved efficacy and potency. ReCode’s lead programs include RCT1100 for the treatment of primary ciliary dyskinesia caused by pathogenic mutations in the DNAI1 gene, and RCT2100 for the treatment of the 10-13% of cystic fibrosis patients who have Class I mutations in the CFTR gene and do not respond to currently approved CFTR modulators. RCT1100 and RCT2100 are inhaled disease-modifying mRNA-based therapies formulated using the SORT LNP delivery platform. ReCode is expanding its pipeline to develop potential therapies for other rare and common genetic diseases, including musculoskeletal, central nervous system, liver and infectious disease indications.

ReCode has been recognized by the San Francisco Business Times and Silicon Valley Business Journal as a Best Place to Work. For more information, visit www.recodetx.com and follow us on LinkedIn and Instagram.

Contacts

Investor Contact:
Anne Marie Fields

Stern IR

annemarie.fields@sternir.com
IR@recodetx.com

Media Contacts:
Erica Jefferson

SVP, Corporate Affairs

ReCode Therapeutics

ejefferson@recodetx.com
650-629-7965

Tara Cooper

The Grace Group

tara@gracegroup.us
650-303-7306

InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million

InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million




InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million

  • Revenues during 2023 reached NIS 356 million, alongside an Adjusted EBITDA1 of NIS 61 million (Approximately 17% of revenues), as compared to an Adjusted EBITDA of NIS 51 million in our preliminary results.
  • The Company’s cash2 on hand was NIS 111 million. Both Q3&Q4 ended with positive EBITDAs and profit from operations3 and represents InterCure’s fourteenth & fifteenth consecutive quarter of profitability4.
  • Revenues for H2 2023 were affected by damages caused by the terrorist attack on October 7, 2023 and the war in Gaza.
  • InterCure is entitled to full compensation from the Israeli authorities for all direct and indirect damages caused to the Southern Facility. To date, InterCure has already received tens of millions of NIS as partial advanced payments from the Israeli authorities.
  • Expects to launch its first products in Germany in the coming months and continues to closely watch developments surrounding Cannabis rescheduling in the U.S.
  • Expects sequential double digit quarterly growth during 2024.

NEW YORK & HERZLIYA, Israel–(BUSINESS WIRE)–InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (“InterCure” or the “Company“) today announced results for the full year ending December 31, 2023. All amounts are expressed in New Israeli Shekels (NIS), unless otherwise noted.


FY2023 Financial Highlights and Milestones

  • Annual revenue for the year ending December 31, 2023 was NIS 356 million, and the adjusted EBITDA for the year ending December 31, 2023 was NIS 61 million, approximately 17% of revenues, as compared to an Adjusted EBITDA of NIS 51 million in our preliminary results.
  • The company’s operating profit was NIS 26 million (before reductions of goodwill and fixed assets of NIS 68 million mainly due to war damage).
  • Both Q3&Q4 2023 represents the fourteenth & fifteenth consecutive quarters of profitability for InterCure5, with both Q3&Q4 2023 showing positive Adjusted EBITDA and profit from operations6.
  • Expanded the Company’s branded products portfolio, launching more than 40 new GMP SKUs during 2023.
  • Continued expansion of the Company’s dedicated medical cannabis pharmacy chain to a of total 24 active locations as of today. As of October 2023, the Company holds 100% of Cannolam LTD including the full rights to Cookies™ international agreements, alongside Israel’s largest chain of dedicated medical cannabis pharmacies, Givol™.
  • Since October 7, 2023, war situation was declared by the Israeli government. As of this date, there is limited access to the Company’s Southern Facility, and parts of the facility are being used by the Israel Defense Forces (the “IDF”), including, among others, the IDF’s medical corps.
  • According to Israeli Law, due to the location of the Company’s Southern Facility, the company is entitled to full compensation for all the direct and indirect damages caused to the Southern Facility by the terrorist attack and the war in Gaza. The Company has begun the process of restoring the Southern Facility, and to date, the Company has already received tens of millions of NIS as advance payments from the Israeli authorities in relation to such compensation.
  • The October 7th terror attack effected the company’s revenues in H2 2023, however, the Company expects to resume sequential quarterly growth during 2024.
  • Continued execution of the Company’s global expansion plan. As recently announced, the Company plans to launch its first products in Germany in the coming months, following the groundbreaking cannabis reform passed.

Alexander Rabinovitch, CEO of InterCure Noted: “Despite extraordinary external challenges this year, InterCure showed solid performance, achieving our fifteenth straight quarter of profitability. This consistent performance highlights the commitment of our team and the effectiveness of the Company’s operational strategy. As the global landscape for pharmaceutical cannabis evolves, we are encouraged by the latest FDA recommendations and the optimistic outlook regarding rescheduling of Cannabis in the U.S. Our leadership in the field, dedication to expanding internationally, enhancing our product offerings, and our focus on adding value for our customers and investors remain pivotal to our ongoing success and growth.”

InterCure is thankful to its managers and employees for their commitment and to its strategic partners in Israel and worldwide who stand with us during this time of war.

About InterCure (dba Canndoc)

InterCure (dba Canndoc) (NASDAQ: INCR) (TASE: INCR) is the leading, profitable, and fastest growing cannabis company outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated “seed-to-sale” model to lead the fastest growing cannabis global market outside of North America.

For more information, visit: https://www.intercure.co

Non-IFRS Measures

This press release makes reference to certain non-IFRS financial measures. Adjusted EBITDA, as defined by InterCure, means earnings before interest, income taxes, depreciation, and amortization, adjusted for changes in the fair value of inventory, share-based payment expense, impairment losses (and gains) on financial assets, non-controlling interest and other expenses (or income). This measure is not a recognized measure under IFRS, does not have a standardized meaning prescribed by IFRS and is therefore unlikely to be comparable to similar measures presented by other companies. InterCure’s method of calculating this measure may differ from methods used by other entities and accordingly, this measure may not be comparable to similarly titled measured used by other entities or in other jurisdictions. InterCure uses this measure because it believes it provides useful information to both management and investors with respect to the operating and financial performance of the company. A reconciliation of Adjusted EBITDA to an IFRS measure (revenue), which is incorporated by reference to this press release, is available in InterCure’s MD&A included in our Annual Report on Form 20-F under the heading “Results of Operations”, available under the Company’s profile on EDGAR at www.sec.gov.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements may include, but are not limited to, the Company’s success of its global expansion plans, its expansion strategy to major markets worldwide, statements relating to the security events in Israel, as well as statements, other than historical facts, that address activities, events or developments that InterCure intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause InterCure’s actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company’s success of its global expansion plans, its continued growth, the expected operations, financial results business strategy, competitive strengths, goals and expansion and growth plans, expansion strategy to major markets worldwide, the impact of the COVID-19 pandemic, the impact of the war in Israel and the war in Ukraine and the conditions of the markets generally. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond InterCure’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to: changes in general economic, business and political conditions, changes in applicable laws, the U.S. regulatory landscapes and enforcement related to cannabis, changes in public opinion and perception of the cannabis industry, and reliance on the expertise and judgment of our senior management. More detailed information about the risks and uncertainties affecting us is contained under the heading “Risk Factors” included in the Company’s most recent Annual Report on Form 20-F and in other filings that we have made and may make with the Securities and Exchange Commission in the future.

1 Adjusted EBITDA means EBITDA for the cannabis sector adjusted for changes in the fair value of inventory, share-based payment expense, impairment losses (and gains) on financial assets, non-controlling interest and other expenses. This is a non-IFRS financial measure and does not have a standardized meaning prescribed by IFRS, please see “Non-IFRS Measures” below.

2 Including Restricted cash.

3 Before non-cash goodwill and property impairments of NIS 68 million mainly due to damages caused by the war.

4 Adjusted EBITDA.

5 Adjusted EBITDA.

6 Before non-cash goodwill and property impairments of NIS 68 million mainly due to damages caused by the war.

Contacts

InterCure Ltd.
Amos Cohen, Chief Financial Officer

amos@intercure.co

Worldwide Clinical Trials Recognized with Coveted 2024 CRO Leadership Awards Based on Customer Feedback for 11th Consecutive Year

Worldwide Clinical Trials Recognized with Coveted 2024 CRO Leadership Awards Based on Customer Feedback for 11th Consecutive Year




Worldwide Clinical Trials Recognized with Coveted 2024 CRO Leadership Awards Based on Customer Feedback for 11th Consecutive Year

Global contract research organization honored as top outsourcing partner, earning high marks in several categories from Industry Standard Research

RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–#CROLeaderWorldwide Clinical Trials (Worldwide), a leading global, full-service contract research organization (CRO), has been recognized for excellence in all five categories in the 2024 CRO Leadership Awards, based on primary market research from Industry Standard Research (ISR) Reports and presented by Clinical Leader and Life Science Leader magazines. This marks the 11th consecutive year that Worldwide is rated as a high-performing CRO based on direct survey feedback from pharmaceutical and biotech professionals, with this year’s distinction augmented by additional honors as a Champion in several pivotal categories.


Highlights from the ISR data include Worldwide being named the highest rated service provider for Project Management Quality, outperforming all other Phase II/III CROs; achieving joint-first position for Operational Excellence among Phase II/III CROs; rating highest Phase II/III service provider for Biostatistics; and outperforming all other Phase II/III CROs for Project Service Delivery in Europe.

Worldwide achieved top marks from sponsor companies across all five core categories, demonstrating comprehensive excellence in:

  • Capabilities (Overall, Big Pharma)
  • Compatibility (Overall, Big Pharma, Small Pharma)
  • Expertise (Overall, Big Pharma, Small Pharma)
  • Quality (Overall, Big Pharma, Small Pharma)
  • Reliability (Overall, Big Pharma, Small Pharma)

Additionally, Clinical Leader recognized organizations that surpassed the weighted average by more than one standard deviation in each of the core categories, earning them the ‘Champion’ title. Worldwide was honored as a Champion in:

  • Compatibility (Big Pharma)
  • Expertise (Big Pharma)
  • Quality (Big Pharma)
  • Reliability (Big Pharma)

“Worldwide’s recognition as a top CRO underscores the dedication our team members have to exceed expectations through collaboration and a real understanding of what our customers want and need,” said Peter Benton, president and CEO of Worldwide. “We are grateful for this industry acknowledgment, marking yet another milestone in our ongoing journey to improve patient lives through clinical research programs, and we remain committed to continued partnerships with our customers to drive innovation and meaningful advancement in healthcare.”

Worldwide’s partnership approach with its customers is anchored in transparent communication, responsiveness, and personalized attention. Earlier this year, Worldwide released the results of its 2024 industry survey, a report that examines the changing perceptions about large and midsize CROs within the pharmaceutical and biotech sectors. The survey data revealed current challenges sponsors are facing with large CROs while highlighting the importance of CRO partnerships and flexibility – underscoring the benefits of Worldwide’s business model. Learn more here.

The CRO Leadership Awards serve as a beacon of trust and quality within the pharmaceutical industry, helping stakeholders identify CRO partners that are not just capable, but exemplary. This year’s awards saw evaluations of 42 contract research organizations across over 20 performance metrics, grounded in robust, direct feedback from customers regarding their experiences over the past 18 months to reflect real-world performance and reliability.

Learn more about Worldwide’s services and achievements here.

About Worldwide Clinical Trials:

Worldwide Clinical Trials (Worldwide) is a leading full-service global contract research organization (CRO) that works in partnership with biotechnology and pharmaceutical companies to create customized solutions that advance new medications – from discovery to reality. Worldwide’s capabilities include bioanalytical laboratory services, Phase I-IV clinical trials, and post-approval and real-world evidence studies – all powered by an accessible team of clinicians, scientists, and researchers who bring first-hand expertise and a collaborative, personalized approach to each clinical program. Worldwide is therapeutically focused on neuroscience, oncology, rare diseases, and cardiometabolic and inflammatory disease. Its global footprint spans nearly 60 countries with more than 3,500 team members. For more information, visit www.worldwide.com.

Contacts

Jill Mastrangelo

Jill.Mastrangelo@Worldwide.com

OmniAb to Participate in Five Investor Conferences in May

OmniAb to Participate in Five Investor Conferences in May




OmniAb to Participate in Five Investor Conferences in May

EMERYVILLE, Calif.–(BUSINESS WIRE)–OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in five investor conferences during the month of May.

  • RBC Capital Markets Global Healthcare Conference, May 14-15 at the InterContinental Barclay Hotel in New York City. Management will participate in a fireside chat on Wednesday, May 15th at 11:30 a.m. Eastern time and will hold one-on-one meetings with investors. A live and archived webcast of the fireside chat will be available in the Investors section of OmniAb’s website.
  • H.C. Wainwright 2nd Annual BioConnect Investor Conference at Nasdaq, May 20 in New York City. Management will participate in a fireside chat on Monday, May 20th at 9:30 a.m. Eastern time and will hold one-on-one meetings with investors.
  • Benchmark 4th Annual Virtual Healthcare House Call 1×1 Investor Conference, May 21-22. Management will participate in a virtual call on Wednesday, May 22nd at 3:00 p.m. Eastern time and will hold one-on-one virtual meetings with investors.
  • Craig-Hallum 21st Annual Institutional Investor Conference, May 29 at The Depot Renaissance Minneapolis Hotel. Management will be holding one-on-one and small group meetings on Wednesday, May 29th with investors.
  • 2024 Leerink Partners Healthcare Crossroads Conference, May 28-30 at the Omni Barton Creek Resort & Spa in Austin, Texas. Management will participate in a fireside chat on Thursday, May 30th at 8:00 a.m. Central time and will hold one-on-one meetings with investors.

About OmniAb®

OmniAb licenses cutting edge discovery research technology to the pharmaceutical and biotech industry to enable the discovery of next-generation therapeutics. Our technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for our partners’ drug development efforts. At the heart of the OmniAb platform is something we call Biological Intelligence™ (BI), which powers the immune systems of our proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.

We believe the OmniAb animals comprise the most diverse host systems available in the industry. Our suite of technologies and methods, including computational antigen design and immunization methods, paired with high-throughput single B cell phenotypic screening and mining of next-generation sequencing datasets with custom algorithms, are used to identify fully-human antibodies with exceptional performance and developability characteristics.

Our proprietary transgenic animals, including OmniRat®, OmniChicken® and OmniMouse® have been genetically modified to generate antibodies with human sequences to streamline the development of human therapeutic candidates. OmniFlic® and OmniClic® are fixed or common light-chain rats and chickens, respectively, designed to facilitate the discovery of bispecific antibodies. OmniTaur™ provides cow-inspired antibodies with unique structural characteristics for challenging targets. OmnidAb™, is an in vivo platform for the discovery of single domain antibodies based upon a human VH scaffold that affinity matures in a chicken host environment to provide a functionally diverse immune repertoire unavailable from mammalian systems. Our proprietary technologies are joined with and leverage OmniDeep™, which is a suite of in silico, AI and machine learning tools for therapeutic discovery and optimization that are woven throughout our various technologies and capabilities. Additionally, an established core competency focused on ion channels and transporters further differentiates OmniAb’s technology and creates opportunities in many important and emerging target classes.

OmniAb technologies can be leveraged for the discovery of a variety of next-generation antibody-based therapeutic modalities, including bi- and multi-specific biologics, antibody-drug conjugates, CAR-T therapies, targeted radiotherapeutics, and many others.

For more information, please visit www.omniab.com.

Contacts

OmniAb, Inc.

Neha Singh, Ph.D.

investors@OmniAb.com
X (Twitter) @OmniAbTech

(510) 768-7760

NOMADX Holdings LLC Launches to Commercialize its Rapid and Highly Sensitive Biological and Chemical Detection Platform and Portfolio of Automated Testing Applications

NOMADX Holdings LLC Launches to Commercialize its Rapid and Highly Sensitive Biological and Chemical Detection Platform and Portfolio of Automated Testing Applications




NOMADX Holdings LLC Launches to Commercialize its Rapid and Highly Sensitive Biological and Chemical Detection Platform and Portfolio of Automated Testing Applications

Powered by pioneering technology licensed from Johns Hopkins University, the NOMADX platform aims to enable anyone to perform the rapid and accurate identification of harmful bacteria and viruses in food, water, air, and clinical applications with sensitivity equivalent to PCR


NEW YORK–(BUSINESS WIRE)–NOMADX Holdings LLC (“NOMADX Holdings”), a private company pioneering new technologies for biological and chemical detection, announced today that it has commenced operations to commercialize a portfolio of innovative products that will enable faster, more accurate portable testing in food, water, and air safety, as well as human healthcare, applications.

NOMADX Holdings, which is an acronym for NanoMolecular Automated Diagnostics, was founded by Wilson Chatterji Ventures (“WCV”) and catalyzed through the asset purchase agreement of RamanID, Inc., founded by Ms. Reem Mahrat, earlier this year. The transaction was facilitated by law firm Foley & Lardner. WCV co-founder and life sciences and med-tech investor and expert, Anjan Chatterji, JD, MBA, LLM, will serve as Chief Executive Officer and Board Member of NOMADX. Chris Wilson, WCV partner and a 30-year senior partner of a multi-billion-dollar hedge fund, has been appointed Chairman of the NOMADX Board. Rounding out the NOMADX senior leadership team are a group of experienced industry executives who will operate from the company’s offices in New York City, New Delhi, India, and Boise, Idaho. They include:

  • Dakota Robinson (Chief Financial Officer): Mr. Robinson is a financial restructuring expert and U.S. Army veteran and West Point graduate with nearly a decade of relevant experience.
  • Jennifer Williams (Chief Operating Officer): Ms. Williams is a marketing and organizational expert with a long legacy in healthcare-focused hedge funds in New York.
  • Lyle Probst, MBA (President, North America): Mr. Probst holds 20+ years of experience within operations and product development and engineering in the diagnostic and related biodefense industries.
  • Rupesh Chaturvedi, Ph.D. (Scientific Advisor): Dr. Chaturvedi is a 20-year, tenured professor at India’s prestigious Jawaharlal Nehru University within its School of Biotechnology with experience in identifying and developing biomedical and life sciences solutions.
  • Ishan Barman, Ph.D. (Scientific Advisor): Dr. Barman is a professor in the Department of Mechanical Engineering at Johns Hopkins University with 15+ years of experience within biomedical imaging, engineering, and entrepreneurialism.

At the core of the NOMADX cartridge-enhanced SERS (Surface-Enhanced Raman Scattering) platform is a patented surface coating that is applied to silicon chips using metallic nanoparticles. The novel technology significantly enhances the electromagnetic and chemical spectral scattering signal of molecules within a sample to create a multi-plex platform. Internal validation studies have demonstrated that these enhancements allow the detection and quantification of a wide range of analytes at single-molecule detection levels. Further studies have shown that the NOMADX platform is as fast and simple to use as an ATP-based test, with results that can exceed the sensitivity, specificity, and speed (1-2-minute results) of traditional PCR testing.

“We are pleased to announce the launch of NOMADX Holdings, the natural selection in the evolution of food safety and human healthcare. The COVID pandemic saw a dramatic rise in the use of testing and created a positive perception of its value in the public. Despite the rapid introduction of tests during this time, it was also clear that very little innovation has taken place in portable, rapid testing over the last 20 years. We also saw the potential for contamination and the testing industry pushed past its limits. This led us to look at ways to disrupt this market and to the founding of NOMADX Holdings,” said Chatterji. “NOMADX aims to commercialize a new generation of powerful detection systems that will enable anyone to perform accurate, rapid, and cost-effective environmental and biological testing. This is not just a step forward, it’s the true allowance of natural selection to advance the evolution of much needed preemptive and offensive technologies and applied applications that enable a safer, healthier future for us all.”

The first commercial application of the NOMADX platform will enable on-site testing for the food safety and public water utilities industries. Foodborne illness, alone, is a preventable public health challenge and multi-billion-dollar burden. The World Health Organization (“WHO”) estimated in 2022 that 600 million – almost 1 in 10 people in the world – fall ill after eating contaminated food and 420,000 die every year, resulting in the loss of 33 million healthy life years. The WHO also estimates 1.7 billion people use a drinking water source contaminated with feces. Further, peer-reviewed studies have shown that approximately 80% of diseases and 50% of child deaths worldwide are related to poor water quality.

The NOMADX platform utilizes label- and label-free testing, on a portable proprietary device, and can detect trace amounts of contaminants, including, but not limited to Salmonella, Listeria monocytogenes, Escherichia coli, PFAS, as well as clinical biomarkers, viruses, and other clinical applications using multi-plex technology on a single chip. With a minute or less of sample prep, rapid testing can be done at a very low cost on food, its packaging, and preparation surfaces, and can also be used for the automated detection of contaminants in water, air, and in vitro. The cartridge and sample, after testing, can be retained for confirmatory testing, as the NOMADX protocol is non-destructive to the sample. Further, spectral data are analyzed with the NOMADX data library and AI-based algorithm to produce results instantly for defined pathogen signatures, as well as those that have corollary signatures that have not yet been defined. The NOMADX platform pipeline will expand to include early detection in the field of oncology and rare diseases, as well as potential therapeutics for companion diagnostics.

For more information about NOMADX platform and the company’s early access program, please visit: www.nomadxholdings.com.

About NOMADX Holdings

NOMADX Holdings LLC, is pioneering new technologies for biological and chemical detection that include innovative products that will enable faster, more accurate testing in food, water, and air safety as well as human healthcare, applications. For more information about NOMADX and its mission to become the natural selection in the evolution of diagnostics, please visit www.nomadxholdings.com.

Contacts

media@nomadxholdings.com

VantAI Collaborates With Google Cloud to Harness NVIDIA GPUs for Building Protein Interaction Foundation Models

VantAI Collaborates With Google Cloud to Harness NVIDIA GPUs for Building Protein Interaction Foundation Models




VantAI Collaborates With Google Cloud to Harness NVIDIA GPUs for Building Protein Interaction Foundation Models

– VantAI will leverage its proprietary large scale structural data and NVIDIA H100 GPUs on Google Cloud to enable a step-change in accuracy for all-atom protein interaction prediction –


– VantAI reports a 3x speedup in training times by switching from NVIDIA A100 to H100 GPUs, leveraging Google Cloud’s A3 virtual machines for large-scale distributed training –

NEW YORK–(BUSINESS WIRE)–#AI–VantAI, a pioneer in generative AI-enabled drug discovery, is working with Google Cloud to power large scale distributed training and further improve internal operations. This collaboration is set to provide VantAI with NVIDIA H100 GPUs, a move that VantAI believes will help accelerate the training of geometric foundation models for making protein-protein interactions programmable.

VantAI’s mission to exponentially expand the space of druggable targets by making protein interactions programmable takes a strong leap forward with this collaboration. Through its proprietary structural proteomics platform, VantAI is on the path to generating structural data for the protein fabric making up entire cells and tissues – a shift in scale that will help unlock significantly larger datasets than previously accessible. By combining this large proprietary dataset with the computational power of NVIDIA H100 GPUs, VantAI will continue to build industry leading all-atom protein interaction foundation models, key to its mission to unlock a new chapter in medicine driven by Proximity Modulators (ProMods), innovative molecules designed to modulate protein interactions. VantAI accomplished a threefold increase in training speeds by transitioning from NVIDIA A100 to H100 GPUs for the same number of nodes already and expects to orchestrate the computational resources efficiently as VantAI uses Google Kubernetes Engine (GKE), leveraging Google Cloud’s A3 virtual machines for the large scale distributed training, as a part of the collaboration with Google Cloud.

“The ability to rationally design molecules that modulate protein interactions has been held back by the lack of data needed to train foundation-scale models,” said Luca Naef, CTO and co-founder of VantAI. “Now that we’ve finally removed this bottleneck through our proprietary data platform, the obvious next step was to apply scale. We are thrilled to work together with Google Cloud in this incredible problem space and believe our collaboration will lay the basis for significant scientific breakthroughs in the near future.”

“Google Cloud is committed to providing the most open ecosystem and helping customers accelerate their digital transformations,” said Shweta Maniar, global director of Life Science Strategy & Solutions, Google Cloud. “Through this new collaboration, VantAI will use Google Cloud’s purpose-built infrastructure to power large scale distributed training that can improve operations and create real-world value for businesses.”

About VantAI

VantAI is at the forefront of applying artificial intelligence technologies to drug discovery. With a cross-disciplinary team of world-class scientists and engineers, VantAI is uniquely suited to power a best-in-class solution for proximity modulation, where the nuance of protein-protein interactions, such as those in protein degradation, has outsized influence on drug success. VantAI has collaborated with and achieved milestones for numerous leading biopharma partners on difficult to drug targets leading to the launch of new development programs with exciting properties. For more information, please visit www.vant.ai.

Contacts

Media

contact@vant.ai

Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024

Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024




Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024

RADNOR, Pa.–(BUSINESS WIRE)–Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the first quarter ended March 31, 2024 before market open on May 8, 2024.


The press release will be available on Marinus’ investor relations website at https://ir.marinuspharma.com/news/default.aspx.

About Marinus Pharmaceuticals

Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company first introduced FDA-approved prescription medication ZTALMY® (ganaxolone) oral suspension CV in the U.S. in 2022 and continues to invest in the potential of ganaxolone in IV and oral formulations to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings. For more information about Marinus visit www.marinuspharma.com.

Contacts

Company
Investors and Media
Molly Cameron

Director, Corporate Communications & Investor Relations

Marinus Pharmaceuticals, Inc.

mcameron@marinuspharma.com